The world of professional tennis has been rocked by another doping scandal, as two lower-ranked players have been provisionally suspended after testing positive for the banned anabolic steroid clostebol. The International Tennis Integrity Agency (ITIA) announced the suspensions on Tuesday, revealing that Latvian Karlis Ozolins (ranked No. 546) and American Daniil Kakhniuk (ranked No. 1,123) both failed drug tests during the same tournament.

The positive samples were collected at an ITF World Tennis Tour event in San Jose, Costa Rica, back in February. Both players' samples contained metabolites of clostebol—the same substance that landed world No. 1 Jannik Sinner a three-month ban in 2024. While Sinner's case made global headlines due to his elite ranking, these latest cases highlight how doping violations can impact players at every level of the sport.

According to the ITIA, Ozolins and Kakhniuk "have the right to appeal their suspensions, but neither has done so." This suggests the players may be accepting the initial findings, though both retain the option to contest the decision. The ITIA has emphasized its commitment to supporting all athletes through the process, stating: "As with all Tennis Anti-Doping Program cases, ITIA support is available to both players, including pro-bono legal aid, independent wellbeing support, and financial assistance to investigate the source of positive findings."

For tennis fans and athletes alike, these cases serve as a stark reminder that anti-doping rules apply uniformly across the sport, from Grand Slam champions to rising stars on the ITF circuit. As the investigations continue, the tennis community will be watching closely to see how these players navigate their suspensions and what lessons can be learned about preventing future violations.